Identifying treatment targets for tumors in neurofibromatosis type 1
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
This study is looking at how benign tumors from neurofibromatosis type 1 can sometimes turn into more serious tumors, and it's for people with NF1 who want to know more about potential new treatments and ways to stop this change from happening.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10888203 on NIH RePORTER |
What this research studies
This research focuses on neurofibromatosis type 1 (NF1), a genetic condition that can lead to the development of benign tumors called neurofibromas, which may progress to malignant peripheral nerve sheath tumors (MPNSTs). The study aims to uncover the biological mechanisms behind this progression and identify potential treatment targets. By developing better models to study these tumors, researchers hope to find new ways to prevent the transformation from benign to malignant tumors and improve treatment options for affected patients. The approach includes genetic analysis and the use of advanced laboratory techniques to explore vulnerabilities in tumor cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 1, particularly those who have developed plexiform neurofibromas.
Not a fit: Patients without a diagnosis of neurofibromatosis type 1 or those who do not have plexiform neurofibromas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent the progression of benign tumors to aggressive cancers in NF1 patients.
How similar studies have performed: Previous research has shown promise in identifying treatment targets for similar tumor types, but this specific approach is novel and aims to address critical gaps in current treatment options.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Largaespada, David Andrew — University of Minnesota
- Study coordinator: Largaespada, David Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.